Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA) >40 ng/ml: Prognostic significance of the preradiation PSA nadir

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 5, 2011, Pages

  Alexander, Abraham S ^a,b   Mydin, Aminudin ^a   Jones, Stuart O ^a   Christie, Jennifer ^a   Lim, Jan T W ^a,b   Truong, Pauline T ^a,b   Ludgate, Charles M ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Androgen deprivation therapy; Neoadjuvant; Prostate cancer; Prostate specific antigen; Radiation therapy

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL DISEASE-FREE SURVIVAL (BDFS); GLEASON SCORES; MULTI VARIATE ANALYSIS; NEOADJUVANT; OVERALL SURVIVAL; PROGNOSTIC FACTORS; PROGNOSTIC SIGNIFICANCE; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE-SPECIFIC ANTIGEN;

ANTIGENS; DISEASE CONTROL; MULTIVARIANT ANALYSIS; PATIENT MONITORING; RADIATION EFFECTS; RADIOTHERAPY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES;

EID: 81855163382     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.11.068     Document Type: Article

References (31)

1. R.A. Stephenson, and J.L. Stanford Population-based prostate cancer trends in the united states: Patterns of change in the era of prostate-specific antigen World J Urol 15 1997 331 335 (Pubitemid 127764016)
2. I.H. Derweesh, P.A. Kupelian, and C. Zippe Continuing trends in pathological stage migration in radical prostatectomy specimens Urol Oncol 22 2004 300 306 (Pubitemid 38993307)
3. J.O. Ung, J.P. Richie, and M.H. Chen Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era Urology 60 2002 458 463 (Pubitemid 35292173)
4. M. Roach III, V. Weinberg, and M. Nash Defining high risk prostate cancer with risk groups and nomograms: Implications for designing clinical trials J Urol 176 2006 S16 S20
5. S.F. Shariat, P.I. Karakiewicz, and C.G. Roehrborn An updated catalog of prostate cancer predictive tools Cancer 113 2008 3075 3099
6. W.T. Lowrance, and P.T. Scardino Predictive models for newly diagnosed prostate cancer patients Rev Urol 11 2009 117 126
7. I.M. Thompson Defining high risk prostate cancer: where do we set the bar? A translational science approach to risk stratification J Urol 176 2006 S21 S26
8. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
9. A.V. D'Amico, K. Cote, and M. Loffredo Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 2002 4567 4573 (Pubitemid 35402960)
10. A.V. D'Amico, J. Moul, and P.R. Carroll Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era J Clin Oncol 21 2003 2163 2172 (Pubitemid 46606365)
11. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
12. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The radiation therapy oncology group protocol 92-02 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
13. M. Roach III, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591 (Pubitemid 351264352)
14. C.A. Lawton, K. Winter, and K. Murray Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946 (Pubitemid 32184600)
15. J. Laverdiere, J.L. Gomez, and L. Cusan Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer Int J Radiat Oncol Biol Phys 37 1997 247 252 (Pubitemid 27138705)
16. A.L. Zietman, J.J. Coen, and W.U. Shipley Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome J Urol 151 1994 640 645 (Pubitemid 24054701)
17. J.M. Kaminski, A.L. Hanlon, and D.L. Joon Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth Int J Radiat Oncol Biol Phys 57 2003 24 28 (Pubitemid 36959735)
18. J. Crook, C. Ludgate, and S. Malone Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 2004 15 23 (Pubitemid 39165464)
19. C.M. Ludgate, D.C. Bishop, and H. Pai Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: The importance of PSA nadir before radiation Int J Radiat Oncol Biol Phys 62 2005 1309 1315 (Pubitemid 40982048)
20. M.J. Zelefsky, O. Lyass, and Z. Fuks Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy J Clin Oncol 16 1998 3380 3385 (Pubitemid 28481636)
21. M. Sumi, H. Ikeda, and K. Tokuuye The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma Int J Radiat Oncol Biol Phys 48 2000 519 528
22. A. Alexander, J. Crook, and S. Jones Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial Int J Radiat Oncol Biol Phys 76 2010 23 30
23. D.A. Kuban, A.M. el-Mahdi, and P.F. Schellhammer Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer Int J Radiat Oncol Biol Phys 32 1995 307 316
24. G. Rodrigues, K. Bae, and M. Roach Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials Int J Radiat Oncol Biol Phys 2010 Jul 6 (Epub ahead of print)
25. I.D. Fleming American Joint Committee on Cancer Staging Manual 5th edition 1997 Lippincott-Raven Philadelphia, PA
26. S.L. Goldenberg, N. Bruchovsky, and M.E. Gleave Low-dose cyproterone acetate plus mini-dose diethylstilbestrol: A protocol for reversible medical castration Urology 47 1996 882 884 (Pubitemid 26198916)
27. D.L. Fitch, S. McGrath, and A.A. Martinez Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation Int J Radiat Oncol Biol Phys 66 2006 1430 1439
28. R. Cheung, S.L. Tucker, and A.L. Lee Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy Int J Radiat Oncol Biol Phys 61 2005 14 19 (Pubitemid 40039100)
29. A. Pollack, G.K. Zagars, and L.G. Smith Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer J Clin Oncol 18 2000 3904 3911
30. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
31. M.J. Zelefsky, Z. Fuks, and M. Hunt High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116 (Pubitemid 34787844)